Data from a recently published, Canadian, clinical trial of high-dose vitamin D as a method to strengthen bones in healthy adults who do not have osteoporesis have had significant and unexpectedly negative results. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: dose, high, outcome, randomized, trial, vitamin D | 12 Comments »
Two sets of results from a major trial focused on the use of supplements to prevent cancer and heart disease are published today in the New England Journal of Medicine. … READ MORE …
Filed under: Diagnosis, Prevention | Tagged: calciferol, cancer, disease, fatty acid, heart, marine n-3, omega-3, Prevention, vitamin D | 12 Comments »
Two sets of data from the 5-year-long VITamin D and OmegA-3 TriaL (VITAL) were published this week in the New England Journal of Medicine. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: acid, fatty, omega, Prevention, vitamin D | 9 Comments »
It has long between understood that there is an association between a man’s serum levels of vitamin D and his risk for prostate cancer in general and clinically significant prostate cancer in particular. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adverse, pathology, radical prostatectomy, risk, vitamin D | 6 Comments »
A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical prostatectomy did better than similar men taking a placebo. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, risk, Treatment, vitamin D | 6 Comments »
A new study by Lambert et al. in the journal Prostate proposes that some forms of chronic prostatic inflammation, driven by low levels of a molecule known as growth differentiation factor-15 (GDF-15), may lead to prostate cancer development. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: GDF-15, inflammation, tumorigenesis, vitamin D | 6 Comments »
Denosumab — marketed as Xgeva and as Prolia — is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream). Denosumab, when give as Xgeva, is specifically indicated for the prevention of skeletal-related events in patients with bone metastases from prostate and other forms of cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, hypocalcemia, risk, side effect, vitamin D | 1 Comment »
